Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02317991
Title Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Recruitment Completed
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma


Nab-paclitaxel + Ramucirumab

Age Groups:
Covered Countries USA

No variant requirements are available.